Table 3 Subgroup analyses for the association of H. pylori status at diagnosis with OS of 56 included studies in the meta-analysis
Subgroups | Number of studies (patients) | Pooled overall survival | Heterogeneity | Meta-regression | |||
|---|---|---|---|---|---|---|---|
HR | 95% CI | Weight (%) | I2 | P | P | ||
Referring to H. pylori a | 0.521 | ||||||
Without | 17 (7404) | 0.86 | 0.73–1.00 | 30.10 | 49.8% | 0.010 | |
With | 39 (9581) | 0.78 | 0.66–0.91 | 69.04 | 76.2% | < 0.001 | |
Region of the study | 0.844 | ||||||
East Asia | 43 (13753) | 0.82 | 0.71–0.94 | 74.63 | 75.0% | < 0.001 | |
Other | 13 (3232) | 0.78 | 0.62–0.94 | 25.37 | 60.6% | 0.002 | |
Sample size | 0.519 | ||||||
< 200 | 26 (2781) | 0.79 | 0.67–0.90 | 38.00 | 20.6% | 0.173* | |
≥ 200 | 30 (14204) | 0.80 | 0.67–0.93 | 62.00 | 82.9% | < 0.001 | |
Maximum follow-up period | 0.300 | ||||||
< 7.0 years | 27 (7926) | 0.87 | 0.75–0.98 | 49.32 | 56.9 | < 0.001 | |
≥ 7.0 years | 27 (8805) | 0.75 | 0.61–0.89 | 46.68 | 74.2 | < 0.001 | |
Unknown | 2 (254) | 0.69 | 0.39–1.22 | 2.01 | 0.0 | 0.975* | |
NOS score | 0.160 | ||||||
≤ 7 | 25 (7182) | 0.90 | 0.79–1.01 | 44.15 | 44.3% | 0.010 | |
> 7 | 31 (9803) | 0.73 | 0.61–0.86 | 55.85 | 74.2% | < 0.001 | |
Statistical analysis | 0.921 | ||||||
Univariate | 29 (7586) | 0.82 | 0.72–0.92 | 49.20 | 36.2% | 0.028 | |
Multivariate | 27 (9399) | 0.81 | 0.65–0.96 | 50.80 | 82.1% | < 0.001 | |
H. pylori-positive rate | 0.487 | ||||||
< 70% | 32 (7679) | 0.76 | 0.64–0.88 | 61.38 | 70.2% | < 0.001 | |
≥ 70% | 21 (8661) | 0.87 | 0.72–1.02 | 38.62 | 70.8% | < 0.001 | |
Unknown | 3 (645) | 0.83 | 0.37–1.29 | 4.40 | 47.8% | 0.147* | |
Examining method of H. pylori | 0.014* | ||||||
Histological | 18 (3934) | 0.70 | 0.52–0.88 | 31.18 | 74.7% | < 0.001 | |
Serological | 7 (4872) | 0.88 | 0.70–1.06 | 13.26 | 39.8% | 0.126* | |
Mix | 6 (2352) | 0.65 | 0.47–0.83 | 13.07 | 52.2% | 0.063* | |
Unknown | 25 (8211) | 0.91 | 0.77–1.04 | 42.49 | 58.1% | < 0.001 | |
Mean age at diagnosis | 0.395 | ||||||
< 65 | 31 (10210) | 0.79 | 0.66–0.91 | 58.17 | 73.4% | < 0.001 | |
≥ 65 | 12 (2991) | 0.74 | 0.54–0.94 | 19.70 | 64.9% | 0.001 | |
Unknown | 12 (3465) | 0.93 | 0.74–1.11 | 22.12 | 63.9% | < 0.001 | |
Proportion of male gender | 0.447 | ||||||
< 65% | 23 (5841) | 0.77 | 0.65–0.90 | 42.02 | 61.0% | < 0.001 | |
≥ 65% | 31 (10794) | 0.85 | 0.71–1.00 | 54.60 | 78.8% | < 0.001 | |
Unknown | 2 (350) | 0.61 | 0.26–0.97 | 3.38 | 0.0% | 0.588* | |
TNM stage b | 0.588 | ||||||
Earlier stage | 14 (6723) | 0.81 | 0.63–0.99 | 24.95 | 67.6% | < 0.001 | |
Other | 38 (9773) | 0.79 | 0.68–0.91 | 68.30 | 72.1% | < 0.001 | |
Unknown | 4 (489) | 0.95 | 0.56–1.34 | 6.75 | 58.9% | 0.063* | |
Curative resection of all patients | 0.949 | ||||||
No | 34 (9925) | 0.84 | 0.72–0.97 | 60.64 | 77.50% | < 0.001 | |
Yes | 22 (7511) | 0.79 | 0.64–0.94 | 39.36 | 67.20% | < 0.001 | |